Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a44a9814bf3d910d

Jump to content

PureTech Health

From Wikipedia, the free encyclopedia
PureTech Health
TypePublic
IndustryHealthcare
Founded2005; 21 years ago (2005)
Headquarters,
Key peopleChristopher Viehbacher (Chairman)
Daphne Zohar (CEO)
ProductsMedicines
RevenueDecrease $4.7 million (2025)[1]
Increase $(98.5) million (2025)[1]
Decrease $(110.1) million (2025)[1]
Websitepuretechhealth.com

PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.

History

[edit]

The company was founded by Daphne Zohar, an American entrepreneur, in 2005.[2] It was the subject of an initial public offering on the London Stock Exchange in June 2015.[3]

Operations

[edit]
Previous logo

Companies which PureTech Health founded include Karuna Pharmaceuticals,[4] Gelesis, which has received FDA approval as a treatment for weight management,[5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders,[6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases,[7] and Follica which is developing new treatments for androgentic alopecia among others.[8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics.[9]

References

[edit]
  1. 1 2 3 "Annual Results 2025". PureTech Health. Retrieved 29 April 2026.
  2. ↑ "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  3. ↑ "PureTech banks $171M in a London IPO to fund its biotech bets". Fierce Biotech. 19 June 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  4. ↑ "PureTech Health surges as Karuna investment rockets 442%". Proactive Investors. 19 November 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  5. ↑ "Gelesis raises $12 million for pill that staves off hunger". BetaBoston.com. May 16, 2014. Archived from the original on August 3, 2014. Retrieved December 14, 2019.
  6. ↑ "Akili Interactive adds $13 million to Series C funding pool". The Pharma Letter. 9 August 2018. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  7. ↑ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  8. ↑ "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study". Morning Star. 13 June 2019. Archived from the original on 1 March 2020. Retrieved 14 December 2019.
  9. ↑ "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.
[edit]